ArticleAnnals of surgical oncology2026
Optimizing Surgical Strategies and Prognostic Outcomes in Duodenal Gastrointestinal Stromal Tumors.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clustered Symptom Trajectories After Pulmonary Resection: Implications for Risk Stratification and Recovery.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDuodenal gastrointestinal stromal tumors (GISTs) are rare, and evidence regarding optimal surgical strategy, perioperative imatinib use, and long-term outcomes remains limited. This study evaluated clinicopathologic characteristics, prognostic factors, and survival outcomes in a large single-center cohort, with emphasis on operative strategy. PATIENTS AND
methodsWe retrospectively analyzed 238 patients with duodenal GISTs who underwent surgery between 2000 and 2020 at Zhongshan Hospital, Fudan University. Limited resection (LR) and pancreaticoduodenectomy (PD) were compared. Prognostic factors for recurrence-free survival (RFS) and overall survival (OS) were assessed using Cox regression analyses, and nomograms were constructed to predict 3- and 5-year outcomes.
resultsTumors were most commonly located in the second portion of the duodenum. LR was performed in 174 patients and PD in 64, with R0 resection achieved in all cases. PD was associated with longer operative time, greater blood loss, and higher complication rates. Neoadjuvant imatinib facilitated tumor downsizing and enabled LR in selected patients. After a median follow-up of 111 months, 5-year RFS and OS were 88.2% and 97.9%, respectively. Tumor size, mitotic index, epithelioid/mixed morphology, and male sex were independent adverse prognostic factors, while adjuvant imatinib was strongly protective. Surgical type did not affect long-term survival, including for tumors in the second duodenal portion. The nomogram demonstrated good predictive performance.
conclusionsWhen R0 resection is feasible, LR may be a safe and effective surgical option for patients with duodenal GISTs. Surgical strategy should be individualized according to tumor characteristics and anatomical considerations.
Indexed as
Identifiers
41973293What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.